Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.

Heartseed will use the new funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.

Heartseed Raises $37 Million In Series C Funding To Accelerate Development Of Ipsc-Derived Stem Cell Therapy For Heart Failure

Description

Company Information

Funding Insights

Heartseed Raises $37 Million In Series C Funding To Accelerate Development Of Ipsc-Derived Stem Cell Therapy For Heart Failure

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information